Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | APEX1 | P27695 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tremetone SCHEMBL4743839 | 1.00 | POLB (0.75) | POLBAPEX1RECQLKDM4ERAB9A | |
| Bitalin A SCHEMBL31469140 | 0.86 | POLB (1.00) | POLBAPEX1RECQLKDM4ERAB9A | |
| Bitalin A SCHEMBL29516695 | 0.86 | POLB (1.00) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL28394415 | 0.84 | POLB (0.65) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL16742283 | 0.83 | POLB (0.57) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL1092598 | 0.80 | TDP1 (0.77) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL20594954 | 0.76 | POLB (0.52) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL29998549 | 0.75 | KDM4E (0.48) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL17728865 | 0.75 | ALDH1A1 (0.53) | POLBAPEX1RECQLKDM4ERAB9A | |
| SCHEMBL17739701 | 0.75 | ALDH1A1 (0.53) | POLBAPEX1RECQLKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040057908-A1 | Oral compositions and use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-03-25 | — | — | US | claimed |
| EP-1399119-A2 | ORAL COMPOSITIONS AND USE THEREOF | University of Rochester (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2002047615-A2 | ORAL COMPOSITIONS AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2002-06-20 | — | — | WO | claimed |
| CN-115466236-A | 2, 3-dihydrobenzofuran compound and preparation method thereof | 巢湖学院 | 2022-12-13 | — | — | CN | disclosed |
| CN-108997368-B | Method for efficiently synthesizing optically active polysubstituted 2, 3-dihydrobenzofuran compound by asymmetric organic phosphine catalysis | 南方科技大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-108997368-A | Method for efficiently synthesizing optically active polysubstituted 2, 3-dihydrobenzofuran compound by asymmetric organic phosphine catalysis | 南方科技大学 | 2018-12-14 | — | — | CN | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| US-20040057908-A1 | Oral compositions and use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-03-25 | — | — | US | disclosed |
| EP-1399119-A2 | ORAL COMPOSITIONS AND USE THEREOF | University of Rochester (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002047615-A2 | ORAL COMPOSITIONS AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040057908-A1 | Oral compositions and use thereof | UGGT1, DPM1, B4GALT1 | POLB 3454/4885APEX1 2125/4885RECQL 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.